Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Vaxart ( (VXRT) ) has issued an update.
On May 12, 2025, Phillip Lee announced his resignation as Chief Financial Officer of Vaxart, Inc., effective upon the appointment of a successor. His resignation was not due to any disagreements with the company, and he will assist with the transition until June 1, 2025. On May 13, 2025, Vaxart appointed Jeroen Grasman as the new Chief Financial Officer, effective May 19, 2025. Grasman, who has over 20 years of experience in biotech financial leadership, previously served as CFO at AltruBio and held significant roles at PACT Pharma and Genentech. His appointment is expected to support Vaxart’s advancement of its oral vaccine programs.
The most recent analyst rating on (VXRT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Spark’s Take on VXRT Stock
According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.
Vaxart’s overall score reflects strong revenue growth and progress in its norovirus vaccine program, which are positive factors. However, significant challenges in profitability and cash flow management, along with uncertainties in the COVID-19 program and bearish technical indicators, weigh heavily on the stock. The proposed reverse stock split may help stabilize the company’s market position, but current risks remain substantial.
To see Spark’s full report on VXRT stock, click here.
More about Vaxart
Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform. The company’s vaccines are designed to be administered in pill form, which can be stored and shipped without refrigeration, eliminating the risk of needle-stick injuries. Vaxart’s current development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV).
Average Trading Volume: 1,936,625
Technical Sentiment Signal: Sell
Current Market Cap: $92.42M
See more insights into VXRT stock on TipRanks’ Stock Analysis page.